Last reviewed · How we verify
Flovent Diskus
At a glance
| Generic name | Flovent Diskus |
|---|---|
| Also known as | Flovent Diskus, 50 mcg, 100mcg, 250 mcg, Fluticasone propionate, Reference |
| Sponsor | Johns Hopkins University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children
- Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers (PHASE1, PHASE2)
- Individualizing Treatment for Asthma in Primary Care (PHASE4)
- Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE (PHASE2)
- The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children (PHASE1)
- Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418) (PHASE4)
- Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) (PHASE3)
- Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flovent Diskus CI brief — competitive landscape report
- Flovent Diskus updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI